Breast Cancer Treatment: Chemotherapy Before Surgery May Be Better for Some Patients
Preoperative chemotherapy as the first line of treatment is to increase the success of surgery later. The National Cancer Centre Singapore (NCCS) shares some facts.
Chemotherapy may form part of the first line of treatment before surgery for patients with locally advanced or some early stage breast cancers, under a new programme at the SingHealth Duke-NUS Breast Centre.
Having a patient undergo chemotherapy as early as possible allows the whole body to be treated and any circulating cancer cells present to be targeted. Doing this lowers the risk of the cancer spreading, allows doctors to observe how well the tumour is responding to chemotherapy, and helps shrink the breast tumour, facilitating breast cancer surgery.
If chemotherapy is able to shrink the tumour significantly, a smaller area of the breast may need to be removed. For some patients, a mastectomy can be avoided, allowing them to safely opt for breast-conserving or reconstructive surgery instead, said
Dr Veronique Tan, Consultant,
SingHealth Duke-NUS Breast Centre.
“Surgery remains necessary as residual live tumour cells are often present. Essentially, patients who respond well to preoperative chemotherapy have more surgical options,” said Dr Tan, who specialises in oncoplastic breast surgery. Because preoperative chemotherapy allows clinicians to directly observe the effects of chemotherapy on a breast cancer, further treatment can be tailored according to the response, said
Dr Lee Guek Eng, Consultant,
Division of Medical Oncology,
National Cancer Centre Singapore (NCCS).
Preoperative Chemotherapy - what are the benefits?
“If the cancer completely resolves after preoperative chemotherapy, this heralds a good sign for the patient. This group of patients tends to have a better outcome. Conversely, for patients with cancers that hardly shrink with chemotherapy, we can then react early by including additional chemotherapy options or expediting surgery,” said Dr Lee, who is part of the team behind the programme.
Another is Dr
Rebecca Dent, Senior Consultant, Division of Medical Oncology, NCCS, who said that preoperative treatment is widely practised in the US and the UK. Up to 80 per cent of patients will respond favourably to chemotherapy, with the response rate usually higher for more aggressive breast cancers, underscoring the case for starting chemotherapy early for these patients.